ArticleScience advances2020
An alternate conformation of HCV E2 neutralizing face as an additional vaccine target.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2.NPJ vaccines · 2026Article
- Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design.Nature communications · 2026Article
- mAbClust with AlphaFold 3 avoids hallucinations to define a quaternary broadly neutralizing HCV epitope.bioRxiv : the preprint server for biology · 2026Article
- Antibody responses to a highly conserved peptide in HCV E2 protein correlate with chronicity or spontaneous clearance of HCV infection.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.Vaccine · 2025Article
- Cryo-EM structures of HCV E2 glycoprotein bound to neutralizing and non-neutralizing antibodies determined using bivalent Fabs as fiducial markers.Communications biology · 2025Article
- Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies.PLoS pathogens · 2025Article
- Non-cognate ligands of hepatitis C virus envelope broadly neutralizing antibodies induce virus-neutralizing sera in mice.Frontiers in immunology · 2025Article
- Article
- Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development.Viruses · 2024Review
- Prospects for developing an Hepatitis C virus E1E2-based nanoparticle vaccine.Reviews in medical virology · 2023Review
- Signatures of VNature communications · 2023Article
- Structures of the Hepaci-, Pegi-, and Pestiviruses envelope proteins suggest a novel membrane fusion mechanism.PLoS biology · 2023Article
- Polyvalent immunization elicits a synergistic broadly neutralizing immune response to hypervariable region 1 variants of hepatitis C virus.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Three-Dimensional Reconstruction of the Hepatitis C Virus Envelope Glycoprotein E1E2 Heterodimer by Electron Microscopic Analysis.Journal of virology · 2023Article
- Article
- Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals.Nature communications · 2022Review
- Recombinant Full-Length Hepatitis C Virus E1E2 Dimer Elicits Pangenotypic Neutralizing Antibodies.Frontiers in immunology · 2022Article
- Isolation and Characterization of Human Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide 3.Microbiology spectrum · 2021Article
- BacMam virus-based surface display for HCV E2 glycoprotein induces strong cross-neutralizing antibodies and cellular immune responses in vaccinated mice.Infectious agents and cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 3 countries.
Netanel TzarumDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-6401-1356
Erick GiangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Rameshwar U KadamDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-1612-9250
Fang ChenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Kenna NagyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-3772-3160
Elias H AugestadCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0917-3971
Rodrigo Velázquez-MoctezumaCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Zhen-Yong KeckDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-1275-7495
Yuanzi HuaDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Robyn L StanfieldDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-9521-9184
Marlene DreuxCIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, Lyon, France.ORCID 0000-0002-6607-4796
Jannick PrentoeCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-2203-9478
Steven K H FoungDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jens BukhCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-7815-4806
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-6469-2419
Mansun LawDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-8934-9756
Scripps Research Institute · USUniversity of Copenhagen · DKStanford University · USUniversité Claude Bernard Lyon 1 · FR
Funding
ZWITTERION SURFACTANT DDMAB FOR IMPROV STABIL OF PROTEINP41RR001209 · NCRR · STANFORD UNIVERSITY · PI SCOTT, EMILY E · 1985 to 2011
$38.9MX-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6MUnderstanding human neutralizing antibodies to hepatitis C virusR01AI079031 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2008 to 2017
$4.6MNovel HCV vaccine antigens targeting conserved neutralizing epitopesU19AI123861 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2016 to 2020
$4.6MStructure and function of Hepacivirus envelope glycoproteinR01AI123365 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN, WILSON, IAN A · 2016 to 2020
$3.1MDissecting virus neutralizing determinants to guide HCV vaccine developmentR01AI106005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2014 to 2017
$1.5MDissecting virus neutralizing determinants to guide HCV vaccine developmentR56AI106005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2013 to 2013
$793kNCRR NIH HHS P41 RR001209NIAID NIH HHS R01 AI079031NIAID NIH HHS R01 AI106005NIAID NIH HHS R01 AI123365NIAID NIH HHS R56 AI106005NIAID NIH HHS U19 AI123861NIGMS NIH HHS P41 GM103393
Abstract
To achieve global elimination of hepatitis C virus (HCV), an effective cross-genotype vaccine is needed. The HCV envelope glycoprotein E2 is the main target for neutralizing antibodies (nAbs), which aid in HCV clearance and protection. E2 is structurally flexible and functions in engaging host receptors. Many nAbs bind to the "neutralizing face" on E2, including several broadly nAbs encoded by the
Indexed as
Hepatitis CViral Hepatitis VaccinesAntibodies, NeutralizingEpitopesHepacivirusHepatitis C AntibodiesHumansAntibodies, NeutralizingEpitopesHepatitis C AntibodiesViral Hepatitis Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.